These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
411 related articles for article (PubMed ID: 11398153)
21. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. Durrington PN; Mackness MI; Bhatnagar D; Julier K; Prais H; Arrol S; Morgan J; Wood GN Atherosclerosis; 1998 May; 138(1):217-25. PubMed ID: 9678787 [TBL] [Abstract][Full Text] [Related]
22. Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study. Tikkanen MJ; Laakso M; Ilmonen M; Helve E; Kaarsalo E; Kilkki E; Saltevo J Diabetes Care; 1998 Apr; 21(4):477-81. PubMed ID: 9571327 [TBL] [Abstract][Full Text] [Related]
23. Effects of gemfibrozil (Lopid) on hyperlipidemia in acitretin-treated patients. Results of a double-blind cross-over study. Vahlquist C; Olsson AG; Lindholm A; Vahlquist A Acta Derm Venereol; 1995 Sep; 75(5):377-80. PubMed ID: 8615057 [TBL] [Abstract][Full Text] [Related]
24. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. Guyton JR; Blazing MA; Hagar J; Kashyap ML; Knopp RH; McKenney JM; Nash DT; Nash SD Arch Intern Med; 2000 Apr; 160(8):1177-84. PubMed ID: 10789612 [TBL] [Abstract][Full Text] [Related]
25. Treatment of dyslipidaemias in patients with established vascular disease: a revival of the fibrates. Milionis HJ; Elisaf MS; Mikhailidis DP Curr Med Res Opin; 2000; 16(1):21-32. PubMed ID: 16422031 [TBL] [Abstract][Full Text] [Related]
26. A comparison of lovastatin, an HMG-CoA reductase inhibitor, with gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic dyslipidemia. Bell DS Clin Ther; 1995; 17(5):901-10. PubMed ID: 8595642 [TBL] [Abstract][Full Text] [Related]
27. Effects of gemfibrozil or simvastatin on apolipoprotein-B-containing lipoproteins, apolipoprotein-CIII and lipoprotein(a) in familial combined hyperlipidaemia. Bredie SJ; Westerveld HT; Knipscheer HC; de Bruin TW; Kastelein JJ; Stalenhoef AF Neth J Med; 1996 Aug; 49(2):59-67. PubMed ID: 8824106 [TBL] [Abstract][Full Text] [Related]
28. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia. Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262 [TBL] [Abstract][Full Text] [Related]
29. Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease. Papadakis JA; Ganotakis ES; Jagroop IA; Winder AF; Mikhailidis DP Int J Cardiol; 1999 Jun; 69(3):237-44. PubMed ID: 10402106 [TBL] [Abstract][Full Text] [Related]
30. Efficacy and tolerability of etofibrate and gemfibrozil in combined hyperlipidaemia. Wolf HR Drugs Exp Clin Res; 1994; 20(3):109-13. PubMed ID: 7956717 [TBL] [Abstract][Full Text] [Related]
31. A crossover comparison of the efficacy and safety of lovastatin and gemfibrozil in the treatment of hyperlipidemic organ transplant recipients. Hanes DS; Nicholson PG; Raval DD; Hooper FL; Behrens MT; Weir MR Am J Ther; 1997; 4(2-3):85-91. PubMed ID: 10423597 [TBL] [Abstract][Full Text] [Related]
32. Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl-coenzyme a reductase inhibitor treatment of combined dyslipidemia. McLaughlin T; Abbasi F; Lamendola C; Leary E; Reaven GM Metabolism; 2002 Oct; 51(10):1355-9. PubMed ID: 12370858 [TBL] [Abstract][Full Text] [Related]
33. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Frick MH; Syvänne M; Nieminen MS; Kauma H; Majahalme S; Virtanen V; Kesäniemi YA; Pasternack A; Taskinen MR Circulation; 1997 Oct; 96(7):2137-43. PubMed ID: 9337181 [TBL] [Abstract][Full Text] [Related]
34. Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid regulation. Zambón D; Ros E; Rodriguez-Villar C; Laguna JC; Vázquez M; Sanllehy C; Casals E; Sol JM; Hernández G Metabolism; 1999 Jan; 48(1):47-54. PubMed ID: 9920144 [TBL] [Abstract][Full Text] [Related]
35. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability. Bredie SJ; de Bruin TW; Demacker PN; Kastelein JJ; Stalenhoef AF Am J Cardiol; 1995 Feb; 75(5):348-53. PubMed ID: 7856526 [TBL] [Abstract][Full Text] [Related]
36. Changes in plasma lipid and apolipoprotein levels between heparin-induced extracorporeal low-density lipoprotein precipitation (HELP) treatments. Lane DM; Alaupovic P; Knight-Gibson C; Dudley VS; Laughlin LO Am J Cardiol; 1995 Jun; 75(16):1124-9. PubMed ID: 7762498 [TBL] [Abstract][Full Text] [Related]